CN1114447C - 含有甘草酸和至少一种具有抗病毒活性的蛋白质的抗病毒药物组合物 - Google Patents

含有甘草酸和至少一种具有抗病毒活性的蛋白质的抗病毒药物组合物 Download PDF

Info

Publication number
CN1114447C
CN1114447C CN98805037A CN98805037A CN1114447C CN 1114447 C CN1114447 C CN 1114447C CN 98805037 A CN98805037 A CN 98805037A CN 98805037 A CN98805037 A CN 98805037A CN 1114447 C CN1114447 C CN 1114447C
Authority
CN
China
Prior art keywords
lysozyme
glycyrrhizic acid
lactoferrin
protein
chicken
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98805037A
Other languages
English (en)
Chinese (zh)
Other versions
CN1255859A (zh
Inventor
R·庞贝
M·宾扎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Publication of CN1255859A publication Critical patent/CN1255859A/zh
Application granted granted Critical
Publication of CN1114447C publication Critical patent/CN1114447C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN98805037A 1997-05-14 1998-05-06 含有甘草酸和至少一种具有抗病毒活性的蛋白质的抗病毒药物组合物 Expired - Fee Related CN1114447C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI001119A IT1291366B1 (it) 1997-05-14 1997-05-14 Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale
ITMI97A001119 1997-05-14

Publications (2)

Publication Number Publication Date
CN1255859A CN1255859A (zh) 2000-06-07
CN1114447C true CN1114447C (zh) 2003-07-16

Family

ID=11377123

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98805037A Expired - Fee Related CN1114447C (zh) 1997-05-14 1998-05-06 含有甘草酸和至少一种具有抗病毒活性的蛋白质的抗病毒药物组合物

Country Status (26)

Country Link
US (1) US6329339B1 (enExample)
EP (1) EP0980254B1 (enExample)
JP (2) JP2001525814A (enExample)
KR (1) KR100592193B1 (enExample)
CN (1) CN1114447C (enExample)
AR (1) AR012849A1 (enExample)
AT (1) ATE212232T1 (enExample)
AU (1) AU740944B2 (enExample)
BG (1) BG64748B1 (enExample)
CA (1) CA2289550A1 (enExample)
CZ (1) CZ291932B6 (enExample)
DE (1) DE69803565T2 (enExample)
DK (1) DK0980254T3 (enExample)
EA (1) EA003126B1 (enExample)
ES (1) ES2170501T3 (enExample)
GE (1) GEP20022672B (enExample)
HU (1) HU224956B1 (enExample)
IL (2) IL132651A0 (enExample)
IT (1) IT1291366B1 (enExample)
PL (1) PL189218B1 (enExample)
PT (1) PT980254E (enExample)
SK (1) SK283584B6 (enExample)
TR (1) TR199902730T2 (enExample)
UA (1) UA63955C2 (enExample)
WO (1) WO1998051334A1 (enExample)
ZA (1) ZA983917B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
AU2003225073A1 (en) * 2002-04-18 2003-11-03 The University Of Iowa Research Foundation Methods of inhibiting and treating bacterial biofilms by metal chelators
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7288250B2 (en) * 2003-09-11 2007-10-30 Critical Therapeutics, Inc. Monoclonal antibodies against HMGB1
WO2007011606A2 (en) * 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
CA2631212A1 (en) * 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
IT1391170B1 (it) * 2008-08-07 2011-11-18 D M G Italia S R L Composizione topica intra-nasale utilizzabile in caso di ostruzione nasale
US9416151B2 (en) 2010-08-25 2016-08-16 Lurong ZHANG Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
EP2608783B1 (en) * 2010-08-25 2018-09-19 Lurong Zhang Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
WO2015125961A1 (ja) 2014-02-21 2015-08-27 国立大学法人東京海洋大学 ノロウィルス不活化剤及びその製造方法、ノロウィルス不活化方法、ノロウィルス不活化用リゾチーム類の製造方法、ノロウィルス感染の予防薬又は治療薬、並びにノロウィルス不活化用皮膚外用剤
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
SG11201806868TA (en) * 2016-02-25 2018-09-27 Applied Biological Laboratories Inc Compositions and methods for protecting against airborne pathogens and irritants
CN109022351B (zh) * 2018-09-28 2021-10-19 广州奇龙生物科技有限公司 重组人溶菌酶的新应用
US20230158124A1 (en) * 2020-04-27 2023-05-25 Guangzhou Century Clinical Research Co., Ltd Drug, food and application of anti-coronavirus infection
CN112135625B (zh) * 2020-04-27 2021-07-06 广州新创忆药物临床研究有限公司 一种预防或治疗covid-19新冠肺炎的药物及其应用
JP7399976B2 (ja) * 2020-04-27 2023-12-18 広州新創憶薬物臨床研究有限公司 Ｃｏｖｉｄ－１９新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用
MX2021005280A (es) 2021-05-04 2022-02-23 Spv Timser S A P I De C V Composicion farmaceutica que contiene triterpenoides pentaciclicos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085800B2 (ja) * 1986-12-19 1996-01-24 エーザイ株式会社 塩化リゾチ−ム及びグリチルリチン酸ジカリウム含有水溶液製剤
JP2838720B2 (ja) * 1989-10-31 1998-12-16 ゼリア新薬工業株式会社 安定な点眼剤
JP4056099B2 (ja) * 1996-05-09 2008-03-05 森永乳業株式会社 水生動物の寄生生物性疾患の予防および治療剤

Also Published As

Publication number Publication date
CZ291932B6 (cs) 2003-06-18
IL132651A0 (en) 2001-03-19
ES2170501T3 (es) 2002-08-01
IT1291366B1 (it) 1999-01-07
EA199901024A1 (ru) 2000-06-26
PL189218B1 (pl) 2005-07-29
GEP20022672B (en) 2002-04-25
HUP0002985A2 (hu) 2001-01-29
EP0980254A1 (en) 2000-02-23
ITMI971119A1 (it) 1998-11-14
DE69803565D1 (de) 2002-03-14
CN1255859A (zh) 2000-06-07
DK0980254T3 (da) 2002-05-06
BG64748B1 (bg) 2006-02-28
TR199902730T2 (xx) 2000-02-21
US6329339B1 (en) 2001-12-11
HUP0002985A3 (en) 2001-04-28
JP2009102370A (ja) 2009-05-14
DE69803565T2 (de) 2002-08-08
HK1028347A1 (en) 2001-02-16
AU7764698A (en) 1998-12-08
ATE212232T1 (de) 2002-02-15
ZA983917B (en) 1998-11-09
IL132651A (en) 2006-10-31
KR100592193B1 (ko) 2006-06-23
PT980254E (pt) 2002-07-31
PL336802A1 (en) 2000-07-17
SK154499A3 (en) 2000-08-14
HU224956B1 (en) 2006-04-28
BG103968A (en) 2000-07-31
UA63955C2 (uk) 2004-02-16
AU740944B2 (en) 2001-11-15
WO1998051334A1 (en) 1998-11-19
CA2289550A1 (en) 1998-11-19
KR20010012419A (ko) 2001-02-15
EP0980254B1 (en) 2002-01-23
JP2001525814A (ja) 2001-12-11
AR012849A1 (es) 2000-11-22
ITMI971119A0 (enExample) 1997-05-14
EA003126B1 (ru) 2003-02-27
CZ399199A3 (cs) 2000-04-12
SK283584B6 (sk) 2003-10-07

Similar Documents

Publication Publication Date Title
CN1114447C (zh) 含有甘草酸和至少一种具有抗病毒活性的蛋白质的抗病毒药物组合物
JPS6137739A (ja) 免疫グロブリン類および治療剤を配合した医薬組成物
CN1451388A (zh) 防治病毒引起非典型性肺炎等传染病的药物
KR102538216B1 (ko) 폴리감마글루탐산을 유효성분으로 포함하는 코로나바이러스(SARS-CoV-2) 감염질환의 예방, 경감 또는 치료용 약학적 조성물
Sidwell et al. Inhibitory effects of recombinant manganese superoxide dismutase on influenza virus infections in mice
US20110027255A1 (en) Composition and Method for Treating Papilloma Virus and Equine Sarcoids
Judd et al. In vivo anti-influenza virus activity of a zinc finger peptide
RU2144832C1 (ru) Противовирусное, противомикробное и противокандидозное средство
EP1473037A1 (en) Treatment of hPMV infections with Ribavirin
HK1028347B (en) Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity
US4344937A (en) Antiviral agent comprising 1-β-D-arabinofuranosylthymine
EP0207116A1 (en) Improvements relating to the treatment control and prevention of rhinovirus infections
CN112190696A (zh) 一种预防或治疗新型冠状病毒的药物组合物及其用途
US12023370B2 (en) Composition for the treatment of COVID-19 infection, and a method of treatment
RU2012352C1 (ru) Противовирусная композиция
JPWO2021198774A5 (enExample)
MXPA99010447A (en) Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity
EP1505991A1 (en) A drugs association against influenza virus
EP0360191A2 (en) Anti-aids virus composition
JPS62212327A (ja) 抗菌剤
JPH0262891A (ja) タンパク尿症改善剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20030716